Episode Details

In this episode of Global Economic Press, Alex Brady discusses a pivotal development in the field of regenerative medicine. Hyagen Medical has launched a national initiative to enhance compliance and education standards within this rapidly evolving industry. The initiative aims to align healthcare providers with Food and Drug Administration guidelines, reduce regulatory risks, and promote ethical practices. As patient interest in regenerative medicine grows and regulatory scrutiny intensifies, Hyagen Medical is taking a clear stance that responsible adoption begins with Food and Drug Administration alignment and informed patient education. The company, based in Lehi, Utah, supports healthcare providers nationwide with Food and Drug Administration-aligned training, regulatory consulting, biologics distribution, and patient education systems designed to reduce regulatory risk and strengthen clinical credibility.

Hyagen Medical's compliance-first model helps clinics navigate Food and Drug Administration regulatory boundaries with confidence, reduce exposure to risk from misleading claims or noncompliant marketing, and build long-term credibility in the biologics landscape. The company emphasizes that regenerative medicine and stem cell science are matters of patient safety, ethical sourcing, and regulatory clarity, rather than political issues. By prioritizing accurate language, transparent education, and adherence to Food and Drug Administration guidance, Hyagen Medical aims to elevate industry standards and public trust. For more information about Hyagen Medical and its initiatives, visit their website at Hyagen Medical.